The Role of GLP-1 in Neuronal Activity and Neurodegeneration

Vitamins and Hormones

Volumn 84, Issue C, 2010, Pages 331-354

  Hölscher, Christian ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INSULIN RECEPTOR;

ALZHEIMER DISEASE; ANIMAL; BLOOD BRAIN BARRIER; BOOK; HUMAN; METABOLISM; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; NERVE DEGENERATION; RECEPTOR, INSULIN;

EID: 78649385516     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381517-0.00013-8     Document Type: Book

References (123)

1. Abbas T., Faivre E., Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res. 2009, 205:265-271.
2. Arluison M., Quignon M., Nguyen P., Thorens B., Leloup C., Penicaud L. Distribution and anatomical localization of the glucose transporter 2 (GLUT2) in the adult rat brain-An immunohistochemical study. J. Chem. Neuroanat. 2004, 28:117-136.
3. Aubert-Pouessel A., Venier-Julienne M.C., Clavreul A., Sergent M., Jollivet C., Montero-Menei C.N., Garcion E., Bibby D.C., Menei P., Benoit J.P. In vitro study of GDNF release from biodegradable PLGA microspheres. J. Control. Release 2004, 95:463-475.
4. Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmeliet P., Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004, 429:413-417.
5. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
6. Banks W.A. The source of cerebral insulin. Eur. J. Pharmacol. 2004, 490:5-12.
7. Begley D.J. Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol. Ther. 2004, 104:29-45.
8. Biessels G.J., Bravenboer B., Gispen W.H. Glucose, insulin and the brain: Modulation of cognition and synaptic plasticity in health and disease: A preface. Eur. J. Pharmacol. 2004, 490:1-4.
9. Biessels G.J., De Leeuw F.E., Lindeboom J., Barkhof F., Scheltens P. Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J. Neurol. Neurosurg. Psychiatry 2006, 77:304-307.
10. Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Muller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., Laferla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 2009, 106:13594-13599.
11. Bradbury J. Hope for AD with NGF gene-therapy trial. Lancet Neurol. 2005, 4:335.
12. Buteau J., Roduit R., Susini S., Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999, 42:856-864.
13. Carro E., Torres A.I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur. J. Pharmacol. 2004, 490:127-133.
14. Carro E., Torres-Aleman I. Insulin-like growth factor I and Alzheimer's disease: Therapeutic prospects?. Expert Rev. Neurother. 2004, 4:79-86.
15. Clarris H.J., Nurcombe V., Small D.H., Beyreuther K., Masters C.L. Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer's disease from hippocampal explants. J. Neurosci. Res. 1994, 38:248-258.
16. Cohen A.C., Tong M., Wands J.R., de la Monte S.M. Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol. Clin. Exp. Res. 2007, 31:1558-1573.
17. Colom L.V., Diaz M.E., Beers D.R., Neely A., Xie W.J., Appel S.H. Role of potassium channels in amyloid-induced cell death. J. Neurochem. 1998, 70:1925-1934.
18. Covaceuszach S., Capsoni S., Ugolini G., Spirito F., Vignone D., Cattaneo A. Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:158-170.
19. Craft S. Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 2005, 26(Suppl. 1):65-69.
20. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: Potential mechanisms and implications for treatment. Curr. Alzheimer Res. 2007, 4:147-152.
21. D'Amico M., Di Filippo C., Marfella R., Abbatecola A.M., Ferraraccio F., Rossi F., Paolisso G. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp. Gerontol. 2010, 45:202-207.
22. Dailey G. Beyond insulin replacement: Addressing the additional needs of the diabetes patient. Diabetes Obes. Metab. 2008, 10(Suppl. 2):83-97.
23. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
24. Doyle M.E., Egan J.M. Pharmacological agents that directly modulate insulin secretion. Pharmacol. Rev. 2003, 55:105-131.
25. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 2007, 113:546-593.
26. Drucker D.J., Nauck M.A. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
27. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 2003, 9:1173-1179.
28. + channel by stimulation of glutamate phosphoinositide-coupled receptors in cultured cerebellar granule cells. Eur. J. Neurosci. 1991, 3:778-789.
29. Freir D.B., Holscher C., Herron C.E. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J. Neurophysiol. 2001, 85:708-713.
30. Frias J.P., Edelman S.V. Incretins and their role in the management of diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2007, 14:269-276.
31. Gallwitz B. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinol. 2006, 31:133-147.
32. Gault V., Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur. J. Pharmacol. 2008, 587:112-117.
33. Gault V.A., Porter W.D., Flatt P.R., Holscher C. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int. J. Obes. 2010, 34, 1341-1344.
34. Gengler S., McClean P., McCurtin R., Gault V., Holscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 2010, 10.1016/j.neurobiolaging.2009.05.012.2010.1002.1014.
35. Gilman C.P., Perry T., Furukawa K., Grieg N.H., Egan J.M., Mattson M.P. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J. Neurochem. 2003, 87:1137-1144.
36. Gispen W.H., Biessels G.J. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 2000, 23:542-549.
37. Goke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: Evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 1995, 7:2294-2300.
38. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 2003, 100:10417-10422.
39. Green D.E. New therapies for diabetes. Clin. Cornerstone 2007, 8:58-63. discussion 64-55.
40. Green B.D., Gault V.A., Mooney M.H., Irwin N., Bailey C.J., Harriott P., Greer B., Flatt P.R., O'Harte F.P. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. J. Mol. Endocrinol. 2003, 31:529-540.
41. Green B.D., Gault V.A., O'Harte F.P., Flatt P.R. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr. Pharm. Des. 2004, 10:3651-3662.
42. Green B.D., Gault V.A., Flatt P.R., Harriott P., Greer B., O'Harte F.P. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch. Biochem. Biophys. 2004, 428:136-143.
43. Green B.D., Lavery K.S., Irwin N., O'Harte F.P., Harriott P., Greer B., Bailey C.J., Flatt P.R. Novel GLP-1 analogue (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta cell function after 3 weeks daily administration in obese diabetic (ob/ob) mice. J. Pharmacol. Exp. Ther. 2006, 318:914-921.
44. Gregory-Evans K., Chang F., Hodges M.D., Gregory-Evans C.Y. Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Mol. Vis. 2009, 15:962-973.
45. Grillo C.A., Piroli G.G., Hendry R.M., Reagan L.P. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res. 2009, 1296:35-45.
46. Haan M.N. Therapy Insight: Type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat. Clin. Pract. Neurol. 2006, 2:159-166.
47. Hallschmid M., Schultes B. Central nervous insulin resistance: A promising target in the treatment of metabolic and cognitive disorders?. Diabetologia 2009, 52:2264-2269.
48. Hamilton A., Holscher C. Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. Neuroreport 2009, 20:1161-1166.
49. Heese K., Low J.W., Inoue N. Nerve growth factor, neural stem cells and Alzheimer's disease. Neurosignals 2006, 15:1-12.
50. Holscher C. Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. Rev. Neurosci. 2005, 16:181-212.
51. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Patents CNS Drug. Discov. 2010, 5, 109-117.
52. Long-Term Potentiation Induced by Stimulation on the Positive Phase of Theta Rhythm: A Better Model for Learning and Memory? 2001, Cambridge University Press, Cambridge. C. Hölscher (Ed.).
53. Holscher C., Li L. New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer's disease?. Neurobiol. Aging. 2008, 31, 1495-1502.
54. Hölscher C., Gengler S., Gault V., Harriott P., Mallot H. Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur. J. Pharmacol. 2007, 561:85-90.
55. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 2004, 490:115-125.
56. Hwang D.H., Lee H.J., Park I.H., Seok J.I., Kim B.G., Joo I.S., Kim S.U. Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther. 2009, 16, 1234-1244.
57. Irwin N., Green B.D., Mooney M.H., Greer B., Harriott P., Bailey C.J., Gault V.A., O'Harte F.P., Flatt P.R. A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. J. Pharmacol. Exp. Ther. 2005, 314:1187-1194.
58. Jacobo S.M., Guerra M.L., Jarrard R.E., Przybyla J.A., Liu G., Watts V.J., Hockerman G.H. The intracellular II-III loops of Cav1.2 and Cav1.3 uncouple L-type voltage-gated Ca2+ channels from glucagon-like peptide-1 potentiation of insulin secretion in INS-1 cells via displacement from lipid rafts. J. Pharmacol. Exp. Ther. 2009, 330:283-293.
59. Janson J., Laedtke T., Parisi J., O'Brien P., Petersen R., Butler P. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53:474-481.
60. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 2003, 27:313-318.
61. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 2002, 18:7-14.
62. Kawasaki H., Springett G.M., Mochizuki N., Toki S., Nakaya M., Matsuda M., Housman D.E., Graybiel A.M. A family of cAMP-binding proteins that directly activate Rap1. Science 1998, 282:2275-2279.
63. Kordower J.H., Mufson E.J., Fox N., Martel L., Emerich D.F. Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates. Exp. Neurol. 1997, 145:586-591.
64. Larsen P.J., Holst J.J. Glucagon-related peptide 1 (GLP-1): Hormone and neurotransmitter. Regul. Pept. 2005, 128:97-107.
65. Lee C.S., Sund N.J., Vatamaniuk M.Z., Matschinsky F.M., Stoffers D.A., Kaestner K.H. Foxa2 controls Pdx1 gene expression in pancreatic beta-cells in vivo. Diabetes 2002, 51:2546-2551.
66. Lee H.J., Kim K.S., Park I.H., Kim S.U. Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS ONE 2007, 2:e156.
67. Leech C., Habener J. Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin. J. Biol. Chem. 1997, 272:17987-17993.
68. Leech C.A., Holz G.G., Chepurny O., Habener J.F. Expression of cAMP-regulated guanine nucleotide exchange factors in pancreatic beta-cells. Biochem. Biophys. Res. Commun. 2000, 278:44-47.
69. Lester-Coll N., Rivera E.J., Soscia S.J., Doiron K., Wands J.R., de la Monte S.M. Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer's disease. J. Alzheimers Dis. 2006, 9:13-33.
70. Li L., Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Res. Rev. 2007, 56:384-402.
71. Li Z.G., Zhang W., Sima A.A. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007, 56:1817-1824.
72. Li Y., Duffy K., Ottinger M., Ray B., Bailey J., Holloway H., Tweedie D., Perry T., Mattson M., Kapogiannis D., Sambamurti K., Lahiri D., Greig N. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 2009, 19. 1205-1219.
73. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5:262-269.
74. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63:1187-1192.
75. Marre M., Shaw J., Brandle M., Bebakar W.M., Kamaruddin N.A., Strand J., Zdravkovic M., Le Thi T.D., Colagiuri S. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med. 2009, 26:268-278.
76. McClean P., Fung K., McCurtin R., Gault V., Hölscher C. Novel GIP and GLP-1 analogues cross the blood brain barrier: A link between diabetes and Alzheimer's disease. 2009 Neuroscience Meeting 2009, Chicago, Society for Neuroscience, Poster no. 529.8/I32.
77. McClean P., Pathasarthy V., Gault V., Holscher C. Liraglutide, a novel GLP-1 analogue, prevents the impairment of learning and LTP in an APP/PS-1 mouse model of Alzheimer's disease 2010.
78. McClean P.L., Gault V.A., Harriott P., Holscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. Eur. J. Pharmacol. 2010, 630:158-162.
79. Mora F., Exposito I., Sanz B., Blazquez E. Selective release of glutamine and glutamic acid produced by perfusion of GLP-1 (7-36) amide in the basal ganglia of the conscious rat. Brain Res. Bull. 1992, 29:359-361.
80. Mueller C., Flotte T.R. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 2008, 15:858-863.
81. Murphy K.G., Bloom S.R. Nonpeptidic glucagon-like peptide 1 receptor agonists: A magic bullet for diabetes?. Proc. Natl. Acad. Sci. USA 2007, 104:689-690.
82. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., Rockenstein E., Chao M.V., et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 2009, 15:331-337.
83. Nagano I., Shiote M., Murakami T., Kamada H., Hamakawa Y., Matsubara E., Yokoyama M., Moritaz K., Shoji M., Abe K. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neruol. Res. 2005, 27:768-772.
84. Oka J.I., Goto N., Kameyama T. Glucagon-like peptide-1 modulates neuronal activity in the rat's hippocampus. Neuroreport 1999, 10:1643-1646.
85. Oka J., Suzuki E., Kondo Y. Endogenous GLP-1 is involved in beta-amyloid protein-induced memory impairment and hippocampal neuronal death in rats. Brain Res. 2000, 878:194-198.
86. Okamoto N., Hore S., Akazawa C., Hayashi Y., Shigemoto R., Mizuno N., Nakanishi S. Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J. Biol. Chem. 1994, 269:1231-1236.
87. Okereke O.I., Selkoe D.J., Pollak M.N., Stampfer M.J., Hu F.B., Hankinson S.E., Grodstein F. A profile of impaired insulin degradation in relation to late-life cognitive decline: A preliminary investigation. Int. J. Geriatr. Psychiatry 2008, 24, 177-182.
88. Perfetti R., Zhou J., Doyle M.E., Egan J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141:4600-4605.
89. Perry T., Greig N.H. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2005, 2:377-385.
90. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., Greig N.H. A novel neurotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 2002, 300:958-966.
91. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 2003, 72:603-612.
92. Perry T., Holloway H.W., Weerasuriya A., Mouton P.R., Duffy K., Mattison J.A., Greig N.H. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol. 2007, 203:293-301.
93. Pi-Sunyer F.X. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad. Med. 2008, 120:5-17.
94. Poon W.W., Blurton-Jones M., Tu C.H., Feinberg L.M., Chabrier M.A., Harris J.W., Jeon N.L., Cotman C.W. Beta-amyloid impairs axonal BDNF retrograde trafficking. Neurobiol. Aging 2009, doi:10.1016/j.neurobiolaging.2009.05.012.
95. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006, 7:940-946.
96. Reger M.A., Watson G.S., Green P.S., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Cherrier M.M., Schellenberg G.D., Frey W.H., Craft S. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J. Alzheimers Dis. 2008, 13:323-331.
97. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Breitner J.C., DeGroodt W., Mehta P., Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008, 70:440-448.
98. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med. 2004, 82:510-529.
99. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol. Cell. Endocrinol. 2009, 297:137-140.
100. Scheen A.J. New therapeutic approaches in type 2 diabetes. Acta Clin. Belg. 2008, 63:402-407.
101. Schulte-Herbruggen O., Braun A., Rochlitzer S., Jockers-Scherubl M.C., Hellweg R. Neurotrophic factors-A tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases?. Curr. Med. Chem. 2007, 14:2318-2329.
102. Shi L., Linville M.C., Tucker E.W., Sonntag W.E., Brunso-Bechtold J.K. Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus. Cereb. Cortex 2005, 15:571-577.
103. Sorenson E.J., et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008, 71:1770-1775.
104. Steen E., Terry B.M., Rivera E., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-Is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
105. Stockhorst U., de Fries D., Steingrueber H.J., Scherbaum W.A. Insulin and the CNS: Effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol. Behav. 2004, 83:47-54.
106. Stoffers D.A., Kieffer T.J., Hussain M.A., Drucker D.J., Bonner-Weir S., Habener J.F., Egan J.M. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000, 49:741-748.
107. Strachan M.W. Insulin and cognitive function in humans: Experimental data and therapeutic considerations. Biochem. Soc. Trans. 2005, 33:1037-1040.
108. Sugaya K., Kwak Y.D., Ohmitsu O., Marutle A., Greig N.H., Choumrina E. Practical issues in stem cell therapy for Alzheimer's disease. Curr. Alzheimer Res. 2007, 4:370-377.
109. Suzuki M., Fujikura K., Inagaki N., Seino S., Takata K. Localization of the ATP-sensitive K+ channel subunit Kir6.2 in mouse pancreas. Diabetes 1997, 46:1440-1444.
110. Terzi D., Zachariou V. Adeno-associated virus-mediated gene delivery approaches for the treatment of CNS disorders. Biotechnol. J. 2008, 3:1555-1563.
111. Townsend M., Shankar G.M., Mehta T., Walsh D.M., Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: A potent role for trimers. J. Physiol. 2006, 572:477-492.
112. Trudeau F., Gagnon S., Massicotte G. Hippocampal synaptic plasticity and glutamate receptor regulation: Influences of diabetes mellitus. Eur. J. Pharmacol. 2004, 490:177-186.
113. van Dam P., Aleman A. Insulin-like growth factor-I, cognition and brain aging. Eur. J. Pharmacol. 2004, 490:87-95.
114. Vilsboll T. Liraglutide: A once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin. Investig. Drugs 2007, 16:231-237.
115. Watson G.S., Craft S. Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer's disease. Eur. J. Pharmacol. 2004, 490:97-113.
116. Watson R.T., Pessin J.E. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog. Horm. Res. 2001, 56:175-193.
117. Wheeler D.B., Randall A., Tsien R.W. Roles of N-type and Q-type Ca2+ channels in supporting hippocampal synaptic transmission. Science 1994, 264:107-111.
118. Winder D.G., Conn P.J. Activation of metabotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine. J. Neurosci. 1993, 13:38-44.
119. Xie L., Helmerhorst E., Taddei K., Plewright B., Van B.W., Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 2002, 22:RC221.
120. Zhao W.Q., Chen H., Quon M.J., Alkon D.L. Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 2004, 490:71-81.
121. Zhao W.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008, 22:246-260.
122. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., Hale P.M., Zdravkovic M., Blonde L. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.
123. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 2009, 5:311-322.